Kazia Therapeutics Limited (KZIA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Sydney, NSW, 호주. 현재 CEO는 John Edwin Friend.
KZIA 을(를) 보유 IPO 날짜 1999-01-06, 9 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $16.2M.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
